Post‐marketing surveillance data for avelumab + axitinib treatment in patients with advanced renal cell carcinoma in Japan: Subgroup analyses by pathological classification
Overall, subgroup analyses of PMS data suggest that avelumab + axitinib improved clinical outcomes in nccRCC in addition to ccRCC.
Authors
- Masahiro Kajita (ORCID: https://orcid.org/0000-0002-1319-0398)
- Makiko Morita (ORCID: https://orcid.org/0000-0003-4803-9994)
- Masashi Sato (ORCID: https://orcid.org/0009-0009-3852-4591)
- Mototsugu Oya (ORCID: https://orcid.org/0000-0002-2048-4263)
- Norio Nonomura (ORCID: https://orcid.org/0000-0002-6522-6233)
- Taito Ito
Institutions
- Keio University (JP)
- Merck Biopharma Co., Ltd. (Japan) (JP)
- The University of Osaka (JP)
Publication Details
- Journal
- International Journal of Urology
- Published
- 2024-12-19
- DOI
- https://doi.org/10.1111/iju.15646
- Citations
- 1
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.42
Funders
- Pfizer
- Merck KGaA